Vise Technologies Inc. Buys Shares of 8,469 Globus Medical, Inc. $GMED

Vise Technologies Inc. bought a new stake in Globus Medical, Inc. (NYSE:GMED) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 8,469 shares of the medical device company’s stock, valued at approximately $739,000.

Several other large investors have also recently bought and sold shares of GMED. Advisory Services Network LLC bought a new stake in Globus Medical in the third quarter valued at approximately $26,000. EverSource Wealth Advisors LLC increased its stake in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares in the last quarter. SBI Securities Co. Ltd. increased its stake in Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 167 shares in the last quarter. Parallel Advisors LLC increased its stake in Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after purchasing an additional 173 shares in the last quarter. Finally, Headlands Technologies LLC increased its stake in Globus Medical by 485.4% in the second quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock valued at $45,000 after purchasing an additional 631 shares in the last quarter. Institutional investors own 95.16% of the company’s stock.

Insider Buying and Selling

In related news, Director David D. Davidar sold 25,000 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the transaction, the director owned 510,175 shares in the company, valued at approximately $41,201,733. This represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 18.38% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on GMED. Royal Bank Of Canada upped their price target on shares of Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Needham & Company LLC upped their price target on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a report on Friday, May 8th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Piper Sandler reiterated an “overweight” rating on shares of Globus Medical in a report on Tuesday. Finally, Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $106.36.

Globus Medical Trading Down 1.8%

Shares of GMED opened at $81.02 on Thursday. Globus Medical, Inc. has a 12 month low of $51.79 and a 12 month high of $101.40. The firm has a fifty day simple moving average of $86.03 and a 200 day simple moving average of $88.19. The stock has a market capitalization of $11.00 billion, a price-to-earnings ratio of 18.84, a PEG ratio of 1.70 and a beta of 0.95.

Globus Medical (NYSE:GMED) last announced its earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The business had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. During the same quarter in the prior year, the company posted $0.68 earnings per share. The firm’s revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, research analysts predict that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.